D-Arginine.

Nitric oxide synthase accepts only the L-enantiomer, so D-arginine is not a substrate and is the standard inactive control in arginine research. Both enantiomers still share the y+ cationic amino acid transporter, so D-arginine occupies carrier capacity without contributing to the pathway.

Lysine, arginine and ornithine all move through the y+ system, and the CAT-1 carrier does not strongly discriminate the arginine enantiomers. Loading one cationic amino acid slows uptake of the others taken at the same time.

Ornithine competes with arginine for the same y+ cationic carrier at the intestinal and cellular membrane. Taking them together splits a fixed transport capacity between them.

A racemic or D-labelled arginine ingredient supplies material the nitric oxide pathway cannot use, so the usable amount is not the label amount. When both appear in one formula only the L-fraction counts toward substrate supply.

Citrulline is converted to arginine by argininosuccinate synthase and lyase, and those enzymes act on the L forms only. Citrulline therefore raises circulating L-arginine and contributes nothing to the D pool. In a racemic or D-labelled product this is the clearest illustration that only half the material enters the pathway.

Arginine and glycine combine through arginine glycine amidinotransferase to form guanidinoacetate, the first committed step toward creatine. The enzyme is stereospecific for L-arginine, so the D enantiomer is not a substrate for it. A DL preparation contributes only its L half to this route.

Guanidinoacetate is methylated to creatine using S-adenosylmethionine, which comes from methionine. That makes methionine the partner on the second half of the same synthesis that arginine starts. As with the first step, only L-arginine feeds the sequence.

Supplying creatine directly bypasses the arginine and glycine route and reduces the demand placed on it. That is the same pathway approached from its end rather than its start. It is a useful comparison point precisely because the D enantiomer cannot contribute to the synthetic route at all.

Ornithine aminotransferase, which handles the ornithine generated when arginase cleaves arginine, requires pyridoxal 5-phosphate. The urea cycle and polyamine routes that follow are all built on the L forms. B6 is a cofactor for the pathway, not a way of making the D enantiomer usable.

Dietary nitrate is reduced to nitrite by oral bacteria and then to nitric oxide in tissue, a route that does not pass through nitric oxide synthase at all. Since nitric oxide synthase accepts only L-arginine, this alternative route is the one that stays open regardless of enantiomer. Naming it here is the honest way to describe what D-arginine cannot do.

Enterocytes convert glutamine to citrulline, which the kidney then converts to arginine, which is why glutamine supports endogenous arginine supply. That whole sequence runs on L amino acids. It is listed to make the point that D-arginine sits outside the network rather than at a corner of it.

Nitric oxide synthase needs tetrahydrobiopterin as a cofactor, and ascorbate helps keep that cofactor in its reduced form. When the cofactor is oxidised the enzyme uncouples and produces superoxide instead. This matters for the L form; the D enantiomer never engages the enzyme in the first place.